Payment overview · 2025
General Payments
$456.25
17 reported records · 8 companies
Healthcare provider profile · identity verified
David Herndon, DO
Allopathic & Osteopathic Physicians|Family Medicine · NEW PORT RICHEY, FL · NPI 1023324035
Verified facts
What the public records show
CMS Open Payments records show David Herndon, DO received $456.25 in general payments during 2025 across 17 reported records.
Corcept Therapeutics accounted for 29.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 200 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $136.29 | 29.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $89.79 | 19.7% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $70.13 | 15.4% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $62.44 | 13.7% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $36.24 | 7.9% | 2 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $24.42 | 5.3% | 1 | 2025 |
| SI-BONE, INC. | Unresolved — no canonical attribution shown | $23.15 | 5.1% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $13.79 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $444.96 | 16 |
| Education | $11.29 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $136.29 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $75.73 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $62.44 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $45.06 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $36.24 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $25.07 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $24.42 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $24.05 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.06 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $13.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 200 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 33 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
33 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
200 | 45 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1544 | 430 |
| Losartan Potassium | Losartan Potassium | 933 | 266 |
| Levothyroxine Sodium | Levothyroxine Sodium | 699 | 201 |
| Amlodipine Besylate | Amlodipine Besylate | 669 | 202 |
| Lisinopril | Lisinopril | 607 | 181 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 563 | 172 |
| Omeprazole | Omeprazole | 518 | 154 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 443 | 138 |
| Gabapentin | Gabapentin | 383 | 118 |
| Metoprolol Succinate | Metoprolol Succinate | 367 | 93 |
| Metformin Hcl | Metformin Hcl | 348 | 103 |
| Pantoprazole Sodium | Pantoprazole Sodium | 339 | 99 |
| Tamsulosin Hcl | Tamsulosin Hcl | 306 | 93 |
| Montelukast Sodium | Montelukast Sodium | 304 | 73 |
| Furosemide | Furosemide | 292 | 97 |
| Trazodone Hcl | Trazodone Hcl | 292 | 87 |
| Hydrochlorothiazide | Hydrochlorothiazide | 290 | 84 |
| Metoprolol Tartrate | Metoprolol Tartrate | 284 | 85 |
| Simvastatin | Simvastatin | 234 | 61 |
| Clopidogrel | Clopidogrel Bisulfate | 218 | 59 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 215 | 73 |
| Metformin Hcl Er | Metformin Hcl | 209 | 63 |
| Potassium Chloride | Potassium Chloride | 204 | 67 |
| Eliquis | Apixaban | 200 | 45 |
| Glimepiride | Glimepiride | 199 | 56 |
| Prednisone | Prednisone | 199 | 89 |
| Escitalopram Oxalate | Escitalopram Oxalate | 196 | 58 |
| Meloxicam | Meloxicam | 195 | 66 |
| Famotidine | Famotidine | 187 | 48 |
| Celecoxib | Celecoxib | 185 | 68 |
| Atenolol | Atenolol | 177 | 47 |
| Buspirone Hcl | Buspirone Hcl | 176 | 58 |
| Duloxetine Hcl | Duloxetine Hcl | 176 | 42 |
| Allopurinol | Allopurinol | 162 | 46 |
| Sertraline Hcl | Sertraline Hcl | 151 | 37 |
| Alprazolam | Alprazolam | 145 | 45 |
| Carvedilol | Carvedilol | 144 | 44 |
| Azithromycin | Azithromycin | 135 | 104 |
| Baclofen | Baclofen | 132 | 43 |
| Finasteride | Finasteride | 124 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 121 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 116 | 39 |
| Oxybutynin Chloride | Oxybutynin Chloride | 114 | 27 |
| Tramadol Hcl | Tramadol Hcl | 110 | 46 |
| Warfarin Sodium | Warfarin Sodium | 102 | 25 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 100 | 27 |
| Alendronate Sodium | Alendronate Sodium | 99 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 99 | 28 |
| Sildenafil Citrate | Sildenafil Citrate | 96 | 27 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 95 | 31 |
| Methylprednisolone | Methylprednisolone | 87 | 70 |
| Tizanidine Hcl | Tizanidine Hcl | 87 | 28 |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 84 | 28 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 77 | 20 |
| Ibuprofen | Ibuprofen | 73 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 72 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 72 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 71 | 15 |
| Bupropion Xl | Bupropion Hcl | 69 | 19 |
| Spironolactone | Spironolactone | 68 | 15 |
| Breyna | Budesonide/Formoterol Fumarate | 67 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 64 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 63 | 17 |
| Nitroglycerin | Nitroglycerin | 59 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 17 |
| Memantine Hcl | Memantine Hcl | 56 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 56 | 18 |
| Propranolol Hcl | Propranolol Hcl | 56 | 15 |
| Nifedipine Er | Nifedipine | 55 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 55 | 35 |
| Mirtazapine | Mirtazapine | 54 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 54 | 13 |
| Glipizide | Glipizide | 53 | 17 |
| Lovastatin | Lovastatin | 52 | 16 |
| Temazepam | Temazepam | 52 | suppressed |
| Topiramate | Topiramate | 51 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 50 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 49 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 16 |
| Valacyclovir | Valacyclovir Hcl | 49 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 46 | 37 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 46 | suppressed |
| Synthroid | Levothyroxine Sodium | 45 | 15 |
| Clonidine Hcl | Clonidine Hcl | 44 | 20 |
| Donepezil Hcl | Donepezil Hcl | 44 | 12 |
| Primidone | Primidone | 44 | 13 |
| Divalproex Sodium | Divalproex Sodium | 43 | suppressed |
| Xarelto | Rivaroxaban | 43 | 14 |
| Chlorthalidone | Chlorthalidone | 42 | 12 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 42 | 27 |
| Bumetanide | Bumetanide | 41 | 12 |
| Enalapril Maleate | Enalapril Maleate | 39 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 38 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | suppressed |
| Nystatin | Nystatin | 36 | 17 |
| Acyclovir | Acyclovir | 34 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Sotalol | Sotalol Hcl | 34 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | 11 |
| Latanoprost | Latanoprost | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | 15 |
| Ondansetron Odt | Ondansetron | 31 | 19 |
| Valsartan | Valsartan | 31 | suppressed |
| Ezetimibe | Ezetimibe | 30 | suppressed |
| Pregabalin | Pregabalin | 30 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 30 | 12 |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Lorazepam | Lorazepam | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 23 | suppressed |
| Jantoven | Warfarin Sodium | 22 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Fluconazole | Fluconazole | 21 | 16 |
| Folic Acid | Folic Acid | 21 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Ozempic | Semaglutide | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 12 |
| Tadalafil | Tadalafil | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Austedo | Deutetrabenazine | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Droplet Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Klor-Con 10 | Potassium Chloride | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Benzonatate | Benzonatate | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Novolin R | Insulin Regular, Human | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $456.25 · 17 records | Corcept Therapeutics | Arikayce, Dexcom G6 Transmitter, ELIQUIS, GEMTESA, Korlym, MOUNJARO, NURTEC ODT, SHINGRIX, TRELEGY ELLIPTA, VYNDAQEL, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error